Loading...
XESMMLC
Market cap173mUSD
Jan 13, Last price  
8.70EUR
1D
0.00%
1Q
45.00%
Jan 2017
-28.69%
IPO
-21.27%
Name

Malin Corporation PLC

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-13.37%
Rev. gr., 5y
8.79%
Revenues
0k
22,900,00042,100,00041,900,00038,000,00034,900,00041,000,000000
Net income
0k
-100.00%
-44,900,000-83,500,000-98,800,000-46,300,000-5,200,00087,700,000-500,00012,900,0000
CFO
-3m
L-55.56%
-17,000,000-22,400,000-27,200,000-13,400,000-4,100,000-3,000,000-4,600,000-7,200,000-3,200,000
Earnings
Feb 26, 2025

Profile

Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.
IPO date
Mar 25, 2015
Employees
Domiciled in
IE
Incorporated in
IE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
3,900
200
Unusual Expense (Income)
NOPBT
(3,900)
(200)
NOPBT Margin
Operating Taxes
(600)
Tax Rate
NOPAT
(3,900)
400
Net income
12,900
-2,680.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
(140,800)
BB yield
140.31%
Debt
Debt current
100
100
Long-term debt
100
100
Deferred revenue
Other long-term liabilities
6,100
Net debt
(110,300)
(173,808)
Cash flow
Cash from operating activities
(3,200)
(7,200)
CAPEX
Cash from investing activities
400
149,100
Cash from financing activities
(141,700)
(200)
FCF
(3,900)
400
Balance
Cash
35,700
173,900
Long term investments
74,800
108
Excess cash
110,500
174,008
Stockholders' equity
118,200
257,000
Invested Capital
5,200
109,192
ROIC
0.27%
ROCE
EV
Common stock shares outstanding
22,300
34,300
Price
4.50
-38.02%
7.26
8.36%
Market cap
100,350
-59.70%
249,018
-16.67%
EV
(9,950)
75,210
EBITDA
(3,700)
100
EV/EBITDA
2.69
752.10
Interest
200
Interest/NOPBT